Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Articles

Page Path
HOME > Intest Res > Volume 16(3); 2018 > Article
Focused Review: Colorectal Cancer Genetic and epigenetic alterations of colorectal cancer
Sung Noh Hong
Intestinal Research 2018;16(3):327-337.
DOI: https://doi.org/10.5217/ir.2018.16.3.327
Published online: July 27, 2018

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Correspondence to Sung Noh Hong, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. Tel: +82-2-3410-3409, Fax: +82-2-3410-6983, gisnhong@gmail.com
• Received: April 18, 2018   • Revised: July 2, 2018   • Accepted: July 3, 2018

© Copyright 2018. Korean Association for the Study of Intestinal Diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 14,559 Views
  • 359 Download
  • 96 Web of Science
  • 96 Crossref
  • 108 Scopus
Full Article

Download PDF Download PDF

  • Colorectal cancer (CRC) arise from multi-step carcinogenesis due to genetic mutations and epigenetic modifications of human genome. Genetic mutations and epigenetic modifications were originally established as 2 independent mechanisms contributing to colorectal carcinogenesis. However, recent evidences demonstrate that there are interactions between these 2 mechanisms. Genetic mutations enable disruption of epigenetic controls while epigenetic modifications can initiate genomic instability and carcinogenesis. This review summarized genetic mutations and epigenetic modifications in colorectal carcinogenesis and molecular classification of CRC subtype based on genetic or epigenetic biomarkers for treatment response and prognosis. Molecular subtypes of CRC will permit the implementation of precision medicine with better outcome of management for CRC.
  • Keywords: Colorectal neoplasms; Mutation; Epigenesis, genetic
Colorectal cancer (CRC) is one of most prevalent malignancy in the world.1 The occurrence of CRC has increased steadily in recent decades, particularly in Eastern Europe, Latin America, and Asia.1 Most CRC occurs sporadically due to genetic mutations and epigenetic modifications of human genome.2 These genetic mutations and epigenetic modifications drive the progression from normal mucosa toward carcinoma by altering signaling pathways that regulate behaviors of cancer. Genetic and epigenetic alterations were originally established as independent mechanisms contributing to colorectal carcinogenesis. However, recent evidences indicate a crosstalk between these 2 mechanisms during colorectal carcinogenesis. Genetic mutations enable modification of several epigenetic controls while epigenetic modifications allow genomic instability and mutagenesis.3 Recently commercialized next-generation sequencing (NGS) have revealed unexpected genetic mutations associated with epigenetic alterations in various cancers. These mutations have the capability to modify cytosine methylation, histone modification, and nucleosome organization. In the meantime, epigenetic silencing of DNA mismatch repair (MMR) genes frequently contribute to genomic instability and lead to mutations of oncogene or tumor suppressor genes.4
Genomic instability includes various genetic or genomic changes ranging from point mutations to chromosomal rearrangement.5 Cytogenetic studies have shown frequent genomic instability in CRC samples. Genomic instability is a definite characteristics of CRC carcinogenesis with 2 distinct pathways: chromosomal instability (CIN) and microsatellite instability (MSI). CIN has been found in approximately 85% of CRC while and the remaining 15% of CRC might have MSI.6
1. Adenoma-Carcinoma Sequence
Vogelstein proposed a multistep carcinogenesis of CRC in 1990 and demonstrated sequential genetic mutations that collaborated in the conversion from normal colonic epithelium to adenocarcinoma.7 This multi-step carcinogenesis comprises genetic mutations in several characteristic genes, such as loss-of-function in APC gene (5q) as an early event of multistep carcinogenesis at the stage of development of adenoma, gain-of-function of KRAS oncogene (12p12) for the progression to large adenoma, and loss-of-function of tumor suppressor genes TP53 (17p) and DCC (18q) for the transition from large adenoma to adenocarcinoma.7 Metastatic lesion can gain additional genetic alterations such as loss of heterozygosity (LOH) on 10q or gains of DNA sequences at 5p and 6p.8
2. Chromosomal Instability
Characteristics of CIN are aneuploidy (abnormal chromosome number) and LOH in cells.9 Although underlying mechanisms of CIN during colorectal carcinogenesis remain unknown, CIN might be caused by chromosomal segregation and defective response to DNA damage that can disturb tumor suppressor genes and activate oncogenes.59
Loss of 17q is commonly identified in CRCs. In situ chromosomal hybridization has identified human TP53 gene positioned on the chromosome 17 long arm (17q21–q22). TP53 is an important cell cycle checkpoint gene. It is known that TP53 inactivation causes uninhibited access in the cell cycle.9 TP53 mutation allows excessive cell proliferation, driving tumor progression and progressing adenoma into invasive carcinoma.79 TP53 mutation is more frequent in non-hypermutated CRCs compared to that in hypermutated CRC which has similar phenomenon in APC mutation.10
APC mutations result from flaws in chromosome segregation11 that activates WNT signaling as an initial critical step during colorectal carcinogenesis. In Cancer Genome Atlas (TCGA) study, WNT signaling is activated in most CRCs.10 Genetic disruption of APC gene that activates WNT signaling has been identified in approximately 80% of CRCs. APC induces proteasomal degradation of CTNNB1. However, mutant APC fails to degrade CTNNB1 which will accumulate in the cytoplasm, transfer into the nucleus, modulate transcriptional activity, and activate MYC and many other oncogenes. In addition to chromosome segregation, APC regulates cell adhesion, differentiation, migration, and apoptosis. Only 5% to 10% CRCs show genetic/epigenetic alterations on genes such as CTNNB1 involved in other WNT pathways.10
Loss and/or LOH of 18q is 1 common genetic alteration in CRCs. It might be because 18q includes SMAD2, SMAD4, and SMAD7 that are transcriptional mediators of transforming growth factor β (TGF-β) signaling.12 TGF-β signaling regulates cell growth, differentiation, and apoptosis, and promotes MYC activation.10 Besides these CINs, the gain of chromosomes 7, 8q, 13q, and 20q and the loss of chromosomes 1p, 4, 8p, and 22q have been reported.31314 CIN is associated with unfavorable outcome of CRC. It can be considered as a prognostic marker.15
3. Microsatellite Instability
Lynch syndrome is caused by genetic mutations in DNA MMR genes including MLH1, MSH2, MSH6, and PMS2. The loss of MMR protein results in genomic instability with numerous genetic alterations frequently found in non-encoding microsatellite regions.16 National Cancer Institute (NCI) recommends MSI status evaluation with a panel of 5 Bethesda markers (3 dinucleotide repeat markers: D2S123, D5S346, D17S250, and 2 mononucleotide repeat markers: BAT 26 and BAT 25) in CRCs.17 MSI status of CRCs can be classified into MSI-high (MSI-H, the presence of instability at least 2 Bethesda markers), MSI-low (MSI-L, the presence of instability in 1 Bethesda marker), or microsatellite stable (MSS; no marker presence). MSI-L and MSS CRCs can be categorized as 1 subtype because they have no significant difference in prognosis.18 Short repetitive sequences within coding regions of tumor suppressor genes can result in loss-of-fuction.19 Although there is mutual exclusivity between CIN and MSI, most CRCs are thought to arise from a similar adenoma-carcinoma sequence. In human MSI-H CRC and cancer cell lines with MSI-H, APC, KRAS, and TP53 have been found to be mutated.2021
MSI-H tumors have been found in about 15% of sporadic CRCs. They are associated with hypermutated subtype of CRCs (defined as cancers with mutation rates of >12/106 bases).10 Although MMR-defective status in 20% of MSI-H CRCs might be due to frameshift mutations or other multiple mutations of MMR gene, 80% of MSI-H CRCs achieve MMR-defective status by biallelic hypermethylation of MLH1 gene. Inactivation of MMR genes can induce MSI-H status with extensive methylation of the promoter region of CpG islands without inducing losses or gains in the chromosomal region (low copy number alteration). These MSI-H CRC have frequent BRAFV600E mutation but infrequent APC and TP53 mutations.
Recent exome sequencing of CRCs and endometrial cancers has revealed significant numbers of non-silent somatic mutations in RNF43 with high prevalence of MSI-H.22 RNF43 is known as an E3 ubiquitin-protein ligase that inhibits WNT signaling.23 A subsequent study has found that RNF43 mutation is accompanied by BRAF mutations in serrated pathway.24
MSI-H CRC tends to occur in females, the elderly, and the proximal colon. MSI-H CRC shows favorable response to 5-fluorouracil (FU).2526 MSI and/or MMR-deficiency can increase somatic mutations in tumor cells, leading to increased neoantigens expression. These changes are associated with abundant tumor-infiltrating lymphocytes and increased susceptibility to checkpoint inhibitors.27 Recently, U.S. Food and Drug Administration has approved pembrolizumab, a monoclonal anti-programmed cell death protein, for MSI-H and MMR-deficient cancers. The response rate to pembrolizumab in 149 patients with MMR-deficient or MSI-H cancers was 39.6% (complete response, 7.4% and partial response, 32.2%).28
4. KRAS Gene
RAS proto-oncogenes (HRAS, KRAS, and NRAS) regulate key cellular signaling pathways including phosphoinositide-3 kinase (PI3K) and mitogen-activated protein kinases (MAPK) pathways.29 Mutations in any RAS gene found in 20% to 25% of all human tumors, of which KRAS mutation accounts for about 85%. In CRC, KRAS mutation occurs in 30% to 50% of CRCs while NRAS mutations only occur in 2.5% to 4.5% of CRCs.30 Primary KRAS mutations will result in hyperplastic changes. However, when KRAS mutations are followed by APC mutation, adenoma progresses to cancer.31 KRAS and NRAS mutations are accepted as predictors of epidermal growth factor receptor (EGFR) inhibitors for treatment of CRC. Monoclonal antibodies to EGFR can induce receptor internalization followed by inhibition of tyrosine kinase and the downstream MAPK signaling. However, KRAS mutations can active guanosine triphosphate-bound protein which subsequently leads to “switch on” of downstream signals permanently. Therefore, CRC with mutant KRAS are resistant to anti-EGFR antibody such as cetuximab and panitumumab.32
Point mutations of KRAS in CRCs are commonly located in codons 12 (82%–87%) and 13 (13%–18%) but infrequently found in codon 61, 63, or 146.33 KRAS mutations might be associated with the phenotype of CRC.34 The association between KRAS mutations status and prognosis in patients with CRC has been controversial.30 Mutation in KRAS codon 12 or BRAF is enriched in proximal CRCs whereas wild-type KRAS/BRAF is increased in distal CRCs.35 KRAS codon 12 mutation including KRASG12C and KRASG12V could be associated with poor survival rate in advanced and recurrent CRCs.36
5. TP53 Mutations
Tumor protein p53 (also known as p53) encoded by TP53 gene is crucial in multicellular organisms as a main cell cycle checkpoint regulator. It prevents cancer formation and progression.9 Hence, TP53 is classified as a tumor suppressor gene. TP53 inactivation allows excessive cell proliferation that drives tumor progression. Traditional concept for multistep carcinogenesis is that TP53 is mainly associated with the evolution from adenoma to invasive cancer. This concept is advocated by frequent LOH or loss of 17q. TP53 mutation is more prevalent in non-hypermutated CRCs than that in hypermutated CRC.10 In addition to loss-of-function, gain-of-function of TP53-mutants also promotes tumor progression and invasion by tumor metabolic reprogramming.37
Epigenomic instability defined as aberrant response in gene expression regulation to environmental variabilities.38 CpG islands methylation in the promoter region of specific gene might alter chromatin conformational structure and DNA accessibility of the transcription apparatus, thereby regulating gene expression.39 Hypermethylation of CpG islands usually prevents expression of a certain gene, including tumor suppressor gene.3
1. CpG Island Methylator Phenotype
Epigenomic instability characterized by multiple CpG islands hypermethylation is referred to as CpG island methylator phenotype (CIMP). CIMP-positive tumors show hypermethylation in promoter regions of tumor suppressor genes that can lead to loss-of-function of genes. CIMP-positive CRCs develop via a serrated pathway.40 However, the prognostic role of CIMP in CRC patients remains contradictory between studies. Such discrepancy might be due to differences in definitions of CIMP.41 Specific CIMP definitions have not been established yet.42 Most studies have reported more unfavorable outcome in patients with CIMP-positive/CIMP-high CRC than those with CIMP-negative/CIMP-low CRC.41 Despite of no association between CIMP status and CRC survival in recent population-based study,42 combinations of CIMP with MSI status or BRAF mutation are associated with CRC survival.41 Most CIMP-positive CRCs reveal MSI-H tumors. Meanwhile, CIMP-positive CRCs with MSS have higher frequency of BRAFV600E mutation. They tend to develop in the proximal colon in later age of females and show poor tumor differentiation.
2. BRAF Mutation
Approximately 8% of CRCs have a point mutation in BRAF such as BRAFV600E and BRAFD594G that is mutually exclusive with KRAS mutations. Patients with BRAFV600E mutation are prevalent with proximal CRC and unfavorable outcome. BRAF mutations such as KRAS and PIK3CA are involved in MAPK and PIK3 pathways in colorectal carcinogenesis.43 BRAF mutations also show resistance to anti-EGFR antibody treatment.44
Based on several distinct molecular entities that have been defined, biologically distinct subgroups with their own clinical course have been proposed.45 Due to recent rapid evolution of high-throughput sequencing technologies such as genome-wide association study, whole exome sequencing, whole genome sequencing, and RNA sequencing, we can generate large-scale sequencing data for genetic and epigenetic alterations of CRCs. High-throughput sequencing data sets can be integrated to enhance information extraction using sophisticated bioinformatics software.
1. Classification Based on Clinical, Morphological, and Molecular Features
Primarily based on status of CIN and DNA methylation, the following 5 molecular subtypes of CRC have been suggested:46 (1) group 1, MSI-H, CIMP-high, methylation of MLH1, chromosomally stable, and BRAF mutation (sporadic MSI-H CRC, 12%); (2) group 2, MSS/MSI-L, CIMP-high, partial methylation of MLH1, chromosomally stable, and BRAF mutation (8%); (3) group 3, MSS/MSI-L, CIMP-low, CIN, KRAS mutation, and MGMT methylation (20%); (4) group 4, mainly MSS, CIMP-negative, and CIN (sporadic and Familial adenomatous polyposis/MUTYH polyposis-associated CRC, 57%);47 and (5) group 5, MSI-H, CIMP-negative, chromosomally stable, and BRAF mutation-negative (Lynch syndrome and familial MSI-H CRC, 3%) (Table 1).
These molecular subtypes are defined based on precancerous lesion and progression of CRC with discrete molecular features. Groups 1 and 2 CRCs may originate from serrated polyps whereas groups 4 and 5 CRCs may arise from adenomatous polyp through adenoma–carcinoma sequence. Group 3 CRCs may develop from adenomatous or serrated polyp. Groups 1 and 4 are considered as having few overlaps of molecular features with each other whereas groups 2, 3 and 5 share molecular features with groups 1 and 4 in different ways.
2. The Cancer Genome Atlas Classification
In 2012, TCGA performed genome-wide analysis for 276 CRCs, including exome sequence, DNA copy number variation (CNV), CpG island methylation, mRNA expression, and microRNA expression (Table 2).10 Exome sequencing has been performed for 224 tumor/normal pairs and 97 subset samples have undergone low-depth-of-coverage whole-genome sequencing. CRCs with >12 mutations/106 bases are defined as hypermutated CRCs (16%) whereas CRCs with <8.24 mutations/106 bases are referred to as non-hypermutated CRCs (84%).
In hypermutated CRCs, three-fourths of them have the expected MSI-H usually with MLH1 hypermethylation and CIMP-positive whereas one-fourth of them have somatic MMR mutations and POLE mutations with >40 mutations/106 bases (ultramutator phenotype). Hypermutated CRCs show frequent mutation in ACVR2A, APC, TGFBR2, BRAF, MSH3, and MSH6 genes. All non-hypermutated CRCs are characterized by MSS and frequent somatic copy number alterations (SCNAs), suggesting that these tumors are associated with chromosomal and sub-chromosomal alterations. Genomic alteration and somatic mutations in non-hypermutated CRC are enriched in APC, TP53, KRAS, PIK3CA, FBXW7, SMAD4, TCF7L2, NRAS, FAM123B, CTNNB1 (β-catenin), ACVR1B, and SOX9 genes. TP53 and APC genes in hypermutated CRCs are mutated less frequently compared to those in non-hypermutated CRCs (20% vs. 60% and 51% vs. 81%, respectively).
WNT signaling is activated in most types of CRCs (94% in non-hypermutated CRCs and 97% in hypermutated CRCs) by either APC inactivation or CTNNB1 activation. TGF-β pathway is inactivated in most hypermutated CRCs (87%) compared to that in non-hypermutated CRCs (27%). WNT signaling activation and TGF-β signaling inactivation will result in MYC activation.
There are no significant biological differences in CNV, expression profile, CpG methylation, or miRNA changes between colon and rectum of non-hypermutated CRCs. However, right-side colon cancers are more likely to be hypermethylated with high frequency of mutation compared to left-side cancers. In addition, TCGA study has suggested CRCs therapeutic approaches, focusing on WNT signaling4849 and MAPK/PI3K signaling.10
3. Molecular Classification Based on Gene Expression Profiles and Clinical Response to EGFR Inhibitor, Cetuximab
Based on gene expression profiles and therapeutic response to cetuximab in 80 patients, the following 6 clinically relevant CRC subtypes have been identified: stem-like, inflammatory, cetuximab resistant transient-amplifying (CR-TA), cetuximab sensitive transient-amplifying (CS-TA), goblet-like, and enterocyte subtypes. These subtypes share similarities with different cell types in colonic crypt, indicating that each subtype is associated with stemness and Wnt signaling. These subtypes can be classified by specific gene profile (Table 3).50 Goblet-like, CS-TA, and CR-TA subtypes have favorable outcome after surgical resection, suggesting tolerable chemotherapy. CR-TA subtype does not respond to cetuximab. It can be identified by filamin A expression. Metastatic CRC with CR-TA subtype may respond to c-MET receptor tyrosine kinase inhibitors.50
4. Consensus Molecular Subtypes of CRC Classification
Although several studies have used gene expression profile for CRCs classifications, results are inconsistent. They fail to provide useful single classification.50515253 To overcome this limitation, an international Colorectal Cancer Subtyping Consortium has shared and analyzed a large-scale data for 4,151 patients with CRC. After applying unsupervised clustering techniques in analytics, they are categorized into 4 consensus molecular subtypes (CMS) (Table 4).54 CMS1 is characterized by immune activation, MSI-H, mutation in BRAF and TGFBR2, SCNA-low, CIMP-positive, and activation in Janus kinase/signal transducers and activators of transcription (JAK/STAT) and caspases pathway (14%). CMS1 CRC tend to occur in the elderly, female, and proximal colon with worse survival after relapse. CMS2 is characterized by canonical feature with mutation in APC and TP53, CIN, SCNA-high, MSS/MSI-L, CIMP-negative, and marked WNT and MYC pathway activation (37%). CMS2 CRC appear to occur in the left-side colon and rectum with superior survival after a relapse. CMS3 is characterized by metabolic features with mutation in KRAS and APC, MSS/MSI-L, SCNA-intermediate, CIMP-low, and exhibiting an epithelial signature and metabolic dysregulation (13%). CMS4 is characterized by mesenchymal feature with SCNA-high, MSS/MSI-L, CIMP-negative, and activation of TGF-β signaling. CMS4 CRCs seem to be diagnosed with advanced stages, showing poorer overall survival (23%). Although CMS classification cannot suggest a therapeutic stratification, extensive datasets can facilitate the understanding of complexity in molecular features of CRC.
5. CRC Subtypes Based on Combinations of Tumor Markers
Development of CRCs involves distinct pathways combined with different genetic and epigenetic alterations. Based on specific combinations of MSI, CIMP, and mutations in BRAF and KRAS, traditional, alternate, and serrated pathways have been proposed in colorectal carcinogenesis.4655 CRCs arising from “traditional” adenoma-carcinoma sequence are characterized by MSS/MSI-L and CIMP-negative without BRAF mutation. CRCs originated from a “serrated” pathway are characterized by CIMP-positive and frequent BRAF mutation. CRCs with additional “alternate” pathway is characterized by MSS/MSI-low, CIMP-low, and KRAS-mutation.5556 Although MSI, CIMP, BRAF-, or KRAS-mutations have been studied extensively, the significance of combinations of these markers has been unclear.56 A total of 563 incident CRCs obtained from a population-based Women's Health Study can be assigned to 5 subtypes with distinct clinicopathological features (Table 5).57 CRCs with type 1 or 5 (MSI-H) showed favorable survival whereas those with type 2 (MSS/MSI-L, CIMP-positive, BRAF-mutation, KRAS wild-type) had unfavorable outcome. Type 2 CRCs are clinicopathologically characterized by the proximal colon location and females with late age onset. Type 5 CRCs are referred to as MSS/MSI-L, CIMP-negative, wild-type BRAF and KRAS CRCs. They have the lowest mortality rates. Type 5 CRCs show proximal colonic location and the youngest onset. Type 4 CRCs, the most prevalent subtype (47%), are characterized by MSS, CIMP-negative, BRAF and KRAS wild-type. Type 5 CRCs are clinicopathologically associated with canonical WNT pathway with APC mutations. They appear to have frequent occurrence in men and in the distal colon and rectum.
Sometimes, it is difficult to define a combination of genetic markers representing a specific subtype of CRC. High throughput techniques provide comprehensive molecular characteristics and allow reclassification of CRC. However, high-throughput data from NGS also show heterogeneous molecular features even for the same CRC sample due to tumor heterogeneity. Tumor bulk consists of diverse cell types with distinct molecular signatures. Intratumoural heterogeneity might be due to genetic variation, stochastic processes, the microenvironment, and cell/tissue plasticity.58 Emerging evidences indicate that tumor heterogeneity provides fuel for resistance to current genetic/epigenetic alteration-guided strategies for anti-cancer therapy.59
Although the number of patients eligible for genome-target therapy has increased over time, medications used for genome-target therapy have only helped a small number of patients with advanced cancer. A cross-sectional study using publicly available data in United States suggested that fewer than 16% of patients were eligible for genome-target therapy while fewer than 7% of patients would benefit from genome-targeted cancer drugs in 2018.60 Current classifications by molecular subtype in CRC are able to improve CRC outcome only in a small portion of patients. This might be due to potentially different classification marker sets or methods, insufficient validation studies, and few evidences of the cost-effectiveness from this still high-cost technique. In addition, evolving technologies have generated vast amounts of molecular biological information which may dilute the meaning of current molecular classifications.
Recent high-throughput analyses regarding comprehensive molecular characterizations of CRCs have enlarged our understanding of their genomic and epigenomic landscapes which have enabled CRCs to be reclassified into biologically and clinically meaningful subtypes.21 In CRCs, genetic and epigenetic events are not indifferent phenomenon. They cooperate for CRC carcinogenesis, although methylation events are more common than point mutations. Integration of genetic and epigenetic alteration in CRC might embody the potential tool for proper diagnostic, prognostic, and therapeutic approaches. Moreover, the identification of key molecular features or pathways specific to a certain CRC subtype may represent potential therapeutic targets, enabling implementation of tailored therapies with better patient management.61
However, heterogeneity can provide seeds for resistance to genome-target therapy. Future cancer therapy should focus on the eradication of heterogeneity. Molecular characteristic exploration of clonal dynamics from tissue samples obtained from resistant site for conventional treatment have most promising guide to the development of treatment strategies that address tumor heterogeneity.58 However, tissue samplings at regular intervals and from multiple sites are major limitations. Theoretically, noninvasive liquid biopsy sampling enables frequent and comprehensive surveillance. NGS produces high-throughput information and demonstrates excellent testing performance using low-input DNA. Integration of NGS with liquid biopsy can maximize overall advantages. NGS-based liquid biopsy might enable minimally invasive and comprehensive genomic profiling of CRC that overwhelms spatial heterogeneity arising from tissue biopsy and limitations in genomic information obtained from candidate gene characterization.62
There is no doubt that an approach based on high throughput molecular information is beneficial for tailored therapies and individualized management in response to the complexity of CRC and the seemingly endless arc of evolution. Further research and validation are urgently needed to adopt these molecular classification systems into clinical practice.

FINANCIAL SUPPORT: The authors received no financial support for the research, authorship, and/or publication of this article.

CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTION: Conception and drafting of manuscript: SNH.

  • 1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683–691.PMID: 26818619.ArticlePubMed
  • 2. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919–932.PMID: 12621137.ArticlePubMed
  • 3. Coppedè F, Lopomo A, Spisni R, Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 2014;20:943–956.PMID: 24574767.ArticlePubMedPMC
  • 4. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012;22:9–20.PMID: 22789535.ArticlePubMedPMC
  • 5. Rao CV, Yamada HY. Genomic instability and colon carcinogenesis: from the perspective of genes. Front Oncol 2013;3:130. PMID: 23734346.ArticlePubMedPMC
  • 6. Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, Croke DT. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene 2002;21:3253–3257.PMID: 12082642.ArticlePubMedPDF
  • 7. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–767.PMID: 2188735.ArticlePubMed
  • 8. Muñoz-Bellvis L, Fontanillo C, González-González M, et al. Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays. Mod Pathol 2012;25:590–601.PMID: 22222638.ArticlePubMedPDF
  • 9. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010;138:2059–2072.PMID: 20420946.ArticlePubMedPMC
  • 10. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330–337.PMID: 22810696.ArticlePubMedPMC
  • 11. Fodde R, Kuipers J, Rosenberg C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001;3:433–438.PMID: 11283620.ArticlePubMedPDF
  • 12. Watanabe T, Kobunai T, Yamamoto Y, et al. Prognostic significance of 18q loss of heterzygosity in microsatellite-stable colorectal cancer. J Clin Oncol 2010;28:e119. PMID: 10.1200/JCO.2009.27.0256. PMID: 20124161.ArticlePubMed
  • 13. Ashktorab H, Schäffer AA, Daremipouran M, Smoot DT, Lee E, Brim H. Distinct genetic alterations in colorectal cancer. PLoS One 2010;5:e8879. PMID: 10.1371/journal.pone.0008879. PMID: 20126641.ArticlePubMedPMC
  • 14. Bruin SC, Klijn C, Liefers GJ, et al. Specific genomic aberrations in primary colorectal cancer are associated with liver metastases. BMC Cancer 2010;10:662. PMID: 21126340.ArticlePubMedPMCPDF
  • 15. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008;57:941–950.PMID: 18364437.ArticlePubMed
  • 16. Iino H, Simms L, Young J, et al. DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut 2000;47:37–42.PMID: 10861262.ArticlePubMedPMC
  • 17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248–5257.PMID: 9823339.PubMed
  • 18. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90–96.PMID: 18832519.ArticlePubMed
  • 19. Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 2015;149:1177–1190.e3.PMID: 26216840.ArticlePubMedPMC
  • 20. Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol 2017;14:235–246.PMID: 27922044.ArticlePubMedPDF
  • 21. Inamura K. Colorectal cancers: an update on their molecular pathology. Cancers (Basel) 2018;10:E26. PMID: 10.3390/cancers10010026. PMID: 29361689.Article
  • 22. Giannakis M, Hodis E, Jasmine Mu X, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet 2014;46:1264–1266.PMID: 25344691.ArticlePubMedPMCPDF
  • 23. Wei W, Li M, Wang J, Nie F, Li L. The E3 ubiquitin ligase ITCH negatively regulates canonical Wnt signaling by targeting dishevelled protein. Mol Cell Biol 2012;32:3903–3912.PMID: 22826439.ArticlePubMedPMC
  • 24. Yan HH, Lai JCW, Ho SL, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut 2017;66:1645–1656.PMID: 27329244.ArticlePubMed
  • 25. Collura A, Lagrange A, Svrcek M, et al. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. Gastroenterology 2014;146:401–411.e1.PMID: 24512910.ArticlePubMed
  • 26. Dorard C, de Thonel A, Collura A, et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med 2011;17:1283–1289.PMID: 21946539.ArticlePubMedPDF
  • 27. Gelsomino F, Barbolini M, Spallanzani A, Pugliese G, Cascinu S. The evolving role of microsatellite instability in colorectal cancer: a review. Cancer Treat Rev 2016;51:19–26.PMID: 27838401.ArticlePubMed
  • 28. First tissue-agnostic drug approval issued. Cancer Discov 2017;7:656.ArticlePDF
  • 29. Irahara N, Baba Y, Nosho K, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010;19:157–163.PMID: 20736745.ArticlePubMedPMC
  • 30. Lee DW, Han SW, Cha Y, et al. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. Cancer 2017;123:3513–3523.PMID: 28513830.ArticlePubMed
  • 31. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789–799.PMID: 15286780.ArticlePubMedPDF
  • 32. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992–3995.PMID: 16618717.ArticlePubMed
  • 33. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438–1446.PMID: 12196370.ArticlePubMedPDF
  • 34. Bazan V, Agnese V, Corsale S, et al. Specific TP53 and/or Kiras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol 2005;16(Suppl 4): iv50–iv55.PMID: 15923430.ArticlePubMedPDF
  • 35. Sinicrope FA, Mahoney MR, Yoon HH, et al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res 2015;21:5294–5304.PMID: 26187617.ArticlePubMedPMC
  • 36. Jones RP, Sutton PA, Evans JP, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer 2017;116:923–929.PMID: 28208157.ArticlePubMedPMCPDF
  • 37. Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett 2015;356(2 Pt A): 197–203.PMID: 24374014.ArticlePubMed
  • 38. Smith CL, Bolton A, Nguyen G. Genomic and epigenomic instability, fragile sites, schizophrenia and autism. Curr Genomics 2010;11:447–469.PMID: 21358990.ArticlePubMedPMC
  • 39. Kim ER, Kim YH. Clinical application of genetics in management of colorectal cancer. Intest Res 2014;12:184–193.PMID: 25349592.ArticlePubMedPMC
  • 40. East JE, Atkin WS, Bateman AC, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut 2017;66:1181–1196.PMID: 28450390.ArticlePubMedPMC
  • 41. Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics 2016;8:25. PMID: 10.1186/s13148-016-0191-8. PMID: 26941852.ArticlePubMedPMC
  • 42. Jia M, Jansen L, Walter V, et al. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study. Br J Cancer 2016;115:1359–1366.PMID: 27811854.ArticlePubMedPMCPDF
  • 43. Lito P, Pratilas CA, Joseph EW, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22:668–682.PMID: 23153539.ArticlePubMedPMC
  • 44. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753–762.PMID: 20619739.ArticlePubMed
  • 45. Linnekamp JF, Hooff SRV, Prasetyanti PR, et al. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. Cell Death Differ 2018;25:616–633.PMID: 29305587.ArticlePubMedPMCPDF
  • 46. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113–130.PMID: 17204026.ArticlePubMed
  • 47. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C-->T: a mutations in colorectal tumors. Nat Genet 2002;30:227–232.PMID: 11818965.ArticlePubMedPDF
  • 48. Hao HX, Xie Y, Zhang Y, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature 2012;485:195–200.PMID: 22575959.ArticlePubMed
  • 49. Li Y, Oliver PG, Lu W, et al. SRI36160 is a specific inhibitor of Wnt/beta-catenin signaling in human pancreatic and colorectal cancer cells. Cancer Lett 2017;389:41–48.PMID: 28043913.ArticlePubMed
  • 50. Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013;19:619–625.PMID: 23584089.ArticlePubMedPMC
  • 51. Budinska E, Popovici V, Tejpar S, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013;231:63–76.PMID: 23836465.ArticlePubMedPMC
  • 52. Marisa L, de Reyniès A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013;10:e1001453. PMID: 10.1371/journal.pmed.1001453. PMID: 23700391.ArticlePubMedPMC
  • 53. Schlicker A, Beran G, Chresta CM, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012;5:66. PMID: 23272949.ArticlePubMedPMCPDF
  • 54. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350–1356.PMID: 26457759.ArticlePubMedPMCPDF
  • 55. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138:2088–2100.PMID: 20420948.ArticlePubMed
  • 56. Samadder NJ, Vierkant RA, Tillmans LS, et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology 2013;145:348–356.e1.PMID: 23665275.ArticlePubMedPMC
  • 57. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015;148:77–87.e2.PMID: 25280443.ArticlePubMed
  • 58. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018;15:81–94.PMID: 29115304.ArticlePubMed
  • 59. Saunders NA, Simpson F, Thompson EW, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 2012;4:675–684.PMID: 22733553.ArticlePubMedPMC
  • 60. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol [published online ahead of print April 17, 2018]. PMID: 10.1001/jamaoncol.2018.1660.Article
  • 61. Alwers E, Jia M, Kloor M, Bläker H, Brenner H, Hoffmeister M. Associations between molecular classifications of colorectal cancer and patient survival: a systematic review. Clin Gastroenterol Hepatol [published online ahead of print January 3, 2018]. PMID: 10.1016/j.cgh.2017.12.038.Article
  • 62. Domínguez-Vigil IG, Moreno-Martínez AK, Wang JY, Roehrl MH, Barrera-Saldaña HA. The dawn of the liquid biopsy in the fight against cancer. Oncotarget 2017;9:2912–2922.PMID: 29416824.ArticlePubMedPMC
Table 1

CRC Molecular Subtype Classification by Jass46

ir-16-327-i001.jpg
Group 1 Group 2 Group 3 Group 4 Group 5
Molecular features
 MSI status MSI-H MSS, MSI-L MSS, MSI-L Mainly MSS MSI-H
 CIMP High High Low Negative Negative
 CIN Stable Stable Unstable Unstable Stable
 KRAS mutation +
 BRAF mutation + + -
Clinical features
 Location Rt>Lt Rt>Lt Lt>Rt Lt>Rt Rt>Lt
 Sex F>M F>M M>F M>F M>F
 Precursor Serrated polyp Serrated polyp Serrated polyp/adenoma Adenoma Adenoma

CRC, colorectal cancer; MSI, microsatellite instability; MSI-H, MSI-high; MSS, microsatellite stable; MSI-L, MSI-low; CIMP, CpG island methylator phenotype; CIN, chromosomal instability; Rt, right; Lt, left; F, female; M, male.

Table 2

CRC Molecular Subtype Classification by TCGA (TCGA classification)10

ir-16-327-i002.jpg
Hypermutated tumor Non-hypermutated tumor
Frequent mutation >12 mutations per 106 bases (median number of total mutations, 728) <8.24 mutations per 106 bases (median number of total mutations, 58)
Proportion of all CRCs 16 84
Tumor site Colon and rectum Common in right-side colon
MSI status Stable High
CIMP status Low High
APC gene mutation 51 81
TP53 gene mutation 20 60
Frequent affected genes (mutation frequency) ACVR2A (63), TGFBR2 (51), BRAF (46), MSH3 (40), and MSH6 (40) KRAS (43), PIK3CA (18), FBXW7 (11), SMAD4 (10), TCF7L2 (9), NRAS (9), FAM123B (7), CTNNB1 (β-catenin) (5), ACVR1B (4), SOX9 (4)
SCNAs - Frequent
WNT signaling activation 97 92
TGF-β signaling inactivation 87 27
PI3K signaling activation 53 50
RTK/RAS signaling activation 80 59
p53 signaling inactivation 47 64

Values are presented as percentage.

CRC, colorectal cancer; TCGA, The Cancer Genome Atlas; MSI, microsatellite instability; CIMP, CpG island methylator phenotype; SCNA, somatic copy number alteration; TGF, transforming growth factor; PI3K, phosphoinositide-3 kinase; RTK, receptor tyrosine kinase.

Table 3

CRC Molecular Subtype Classification by Linking Gene Expression Profiles with Corresponding Clinical Response to Cetuximab50

ir-16-327-i003.jpg
Subtypes Stem-likea Inflammatoryb Transient-amplifyingc Goblet-liked Enterocytee
Cetuximab resistant Cetuximab sensitive
Signature genes SFRP2, +ZEB1 RARRES3 CFTR, FLNA CFTR, (FLNA) MUC2, TFF3 MUC2, (TFF3)
Biomarkers for qRT-PCR SFRP2+ RARRES3+ CFTR+, FLNA+ CFTR+, FLNA− MUC2+, TFF3+ MUC2+, TFF3−
Biomarkers for IHC ZEB1+ - CFTR CFTR MUC2+, TFF3+ MUC2+, TFF3−
Correlated crypt location Base NS Either Either Top Top
Disease-free survival Poor Intermediate Poor Good Good Intermediate
Adjuvant treatment Chemotherapy (FORFIRI) Chemotherapy (FORFIRI) Watchful surveillance Watchful surveillance Watchful surveillance Chemotherapy (FORFIRI)
Metastatic treatment Chemotherapy (FORFIRI) Other therapy c-MET inhibitor Cetuximab Chemotherapy (FORFIRI) or other therapy Other therapy

aHigh expression of WNT signaling targets plus stem cell, myoepithelial, and mesenchymal genes with low expression of differentiation markers.

bComparatively high expression of chemokines and interferon-related genes.

cHeterogeneous collection of samples with variable expression of stem cell and WNT-target genes.

dHigh mRNA expression of goblet-specific MUC2 and TFF3.

eHigh expression of enterocyte-specific genes.

CRC, colorectal cancer; qRT-PCR, real-time quantitative RT-PCR; IHC, immunohistochemistry.

Table 4

CRC Molecular Subtype Classification by Gene Expression Profiling (CMS Classification)54

ir-16-327-i004.jpg
CMS1 (MSI-immune) CMS2 (canonical) CMS3 (metabolic) CMS4 (mesenchymal)
% of all CRCsa 14 37 13 23
Mutation profile BRAF, TGFBR2 APC, TP53, CIN KRAS, APC -
SCNA Low High Intermediate High
MSI status MSI-high MSS/MSI-low MSS/MSI-low MSS/MSI-low
CIMP High/low Negative Low Negative
Pathway analysis JAK/STAT and caspases pathway WNT and MYC activation; cell cycle pathway Metabolic dysregulation; epithelial signature TGF-β activation; stromal infiltration, EMT activation, matrix remodeling; angiodysplasia
MicroRNA - High expression of the miR-17-92 cluster Low expression of let-7 miR family Low expression of miR-200 family
Clinical and pathological variables
 Clinical characteristics Female, old-onset - - -
 Site Right colon Left colon and rectum Left, right colon, and rectum Left colon and rectum
 Stage - - - Advanced stage (III and IV)
 Histologic grade Higher histologic grade - - -
 Prognosis Worse survival after relapse Superior survival after relapse - Worse relapse-free and overall survival

aMixed type (15%).

CRC, colorectal cancer; CMS, consensus molecular subtype; CIN, chromosomal instability; SCNA, somatic copy number alteration; MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype; JAK, Janus kinase; STAT, signal transducers and activators of transcription; TGF, transforming growth factor; EMT, epithelial-mesenchymal transition.

Table 5

CRC Molecular Subtype Classification by MSI, CIMP, and Mutations in BRAF and KRAS57

ir-16-327-i005.jpg
Type 1 Type 2 Type 3 Type 4 Type 5
% of CRCs 7 4 26 47 7
MSI MSI-high MSS/MSI-low MSS/MSI-low MSS/MSI-low MSS/MSI-low
CIMP Positive Positive Negative Negative Negative
BRAF Mutation Mutation Wild-type Wild-type Wild-type
KRAS Wild-type Wild-type Mutation Wild-type Wild-type
CRC specific 5-yr survival (%) 89.5 49.2 72.4 82.5 93.1
Clinical characteristics Oldest-onset, female Old-onset, female - Male Youngest-onset, CRC family history
Site Proximal colon Proximal colon - Distal colon and rectum Proximal colon
Proposed molecular pathway MSI
BRAF mutation
CIMP-positive		 BRAF mutation
CIMP-positive		 KRAS mutation Canonical pathway with APC mutation MSI

CRC, colorectal cancer; MSI, microsatellite instability; CIMP, CpG island methylator phenotype; MSS, microsatellite stable.

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Evaluation of Epigenetic Markers in the Diagnosis and Prognosis of Colorectal Cancer
      Adriana Abigail Ruiz-Quinga, Vicente Rubén Noriega-Puga
      Salud, Ciencia y Tecnología.2025; 5: 1139.     CrossRef
    • MUC2 expression modulates immune infiltration in colorectal cancer
      Christophe M. Raynaud, Ayesha Jabeen, Eiman I. Ahmed, Satanay Hubrack, Apryl Sanchez, Shimaa Sherif, Ahmad A. Al-Shaibi, Bernice Lo, Jessica Roelands, Davide Bedognetti, Wouter Hendrickx
      Frontiers in Immunology.2025;[Epub]     CrossRef
    • Aptamer-directed tyramide signal amplification for ultrasensitive detection of small extracellular vesicles for temporally heterogenous colorectal cancer
      Byung Seok Cha, Eun Sung Lee, Junhyeong Kim, Jinseo Son, Doyeon Kim, Seokjoon Kim, Ki Soo Park
      Sensors and Actuators B: Chemical.2025; 431: 137411.     CrossRef
    • The functional correlation between mir-16-5p and BIRC5 gene in colorectal cancer: integrated analysis of transcriptomics and in vitro validation
      Elif Sibel Aslan, Cuneyd Yavas, Nermin Akcali, Sajjad Eslamkhah, Gulsen Meral, Lutfiye Karcioglu Batur
      Molecular Biology Reports.2025;[Epub]     CrossRef
    • GAS5 rs145204276 Ins/Del Polymorphism Is Associated with CRC Susceptibility in a Romanian Population
      Cecil Sorin Mirea, Michael Schenker, Bianca Petre-Mandache, Mihai-Gabriel Cucu, Georgiana-Cristiana Camen, Ionică Daniel Vîlcea, Bogdan Cristian Albu, Cosmin Vasile Obleagă, Mihai Călin Ciorbagiu, Ioana Streață, Răzvan Mihail Pleșea, Anca-Lelia Riza, Flor
      International Journal of Molecular Sciences.2025; 26(7): 3078.     CrossRef
    • Determining and characterizing circulating nucleosomes in advanced cancer with electrochemical biosensors assisted by magnetic supports and proteomic technologies
      Sandra Tejerina-Miranda, Elisa Carral-Ibarra, Maria Gamella, Ana Montero-Calle, María Pedrero, José M. Pingarrón, Rodrigo Barderas, Susana Campuzano
      Biosensors and Bioelectronics.2025; : 117582.     CrossRef
    • Unveiling Commonalities and Differences in Genetic Regulations via Two-Way Fusion
      Biao Mei, Yu Jiang, Yifan Sun
      Journal of Computational Biology.2024; 31(9): 834.     CrossRef
    • Potential molecular mechanisms of myrtenal against colon cancer: A systematic review
      Lokesh Kumar Boopathy, Anitha Roy, Thiyagarajan Gopal, Rakhee Rathnam Kalari Kandy, Madan Kumar Arumugam
      Journal of Biochemical and Molecular Toxicology.2024;[Epub]     CrossRef
    • Long-term effects of the Hebei Spirit oil spill on the prevalence and incidence of allergic disorders
      Se Hyun Hwang, Yong-Jin Lee, Yun-Hee Choi, Da-An Huh, Min-Sung Kang, Kyong Whan Moon
      Science of The Total Environment.2024; 912: 168801.     CrossRef
    • Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer
      Xia Li, Jingjing Li, Jie Li, Nannan Liu, Liwei Zhuang
      BMC Genomics.2024;[Epub]     CrossRef
    • Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers
      Arefeh Zabeti Touchaei, Sogand Vahidi, Ali Akbar Samadani
      Clinical and Experimental Medicine.2024;[Epub]     CrossRef
    • Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value
      Somayeh Igder, Mozhdeh Zamani, Shima Fakher, Morvarid Siri, Hassan Ashktorab, Negar Azarpira, Pooneh Mokarram, Sowjanya Thatikonda
      Disease Markers.2024; 2024: 1.     CrossRef
    • The Crucial Roles of Diet, Microbiota, and Postbiotics in Colorectal Cancer
      Rüya Kuru-Yaşar, Özlem Üstün-Aytekin
      Current Nutrition Reports.2024; 13(2): 126.     CrossRef
    • Plasma-Derived Extracellular Vesicles and Non-Extracellular Vesicle Components from APCMin/+ Mice Promote Pro-Tumorigenic Activities and Activate Human Colonic Fibroblasts via the NF-κB Signaling Pathway
      Luis A. Arteaga-Blanco, Andrew E. Evans, Dan A. Dixon
      Cells.2024; 13(14): 1195.     CrossRef
    • Discovery and validation of colorectal cancer tissue-specific methylation markers: a dual-center retrospective cohort study
      Qinxing Cao, Zhenjia Dan, Nengyi Hou, Li Yan, Xingmei Yuan, Hejiang Lu, Song Yu, Jiangping Zhang, Huasheng Xiao, Qiang Liu, Xiaoyong Zhang, Min Zhang, Minghui Pang
      Clinical Epigenetics.2024;[Epub]     CrossRef
    • The prognostic and therapeutic potential of vimentin in colorectal cancer
      Zahra Kalaei, Ali Akbar Shekarchi, Mohammad Hojjat-Farsangi, Pooya Jalali, Farhad Jadidi-Niaragh
      Molecular Biology Reports.2024;[Epub]     CrossRef
    • Cold-pressed extraction of perilla seed oil enriched with alpha-linolenic acid mitigates tumour progression and restores gut microbial homeostasis in the AOM/DSS mice model of colitis-associated colorectal cancer
      Chawin Korsirikoon, Peerapa Techaniyom, Aikkarach Kettawan, Thanaporn Rungruang, Chanatip Metheetrairut, Pinidphon Prombutara, Aurawan Kringkasemsee Kettawan, Mozaniel Santana de Oliveira
      PLOS ONE.2024; 19(12): e0315172.     CrossRef
    • Exploring the Complexity of Pan-Cancer: Gene Convergences and in silico Analyses
      Leandro Teodoro, Ana Claudia Carreira, Mari Sogayar
      Breast Cancer: Targets and Therapy.2024; Volume 16: 913.     CrossRef
    • Identification of an m6A‐related lncRNA prognostic signature in colorectal cancer
      Zhi‐Liang Shi, Xiaoling Yang, Cheng‐Long Shen, Guo‐Qiang Zhou
      Journal of Biochemical and Molecular Toxicology.2023;[Epub]     CrossRef
    • IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression
      Xiaoli He, Nan Wu, Renlong Li, Haohao Zhang, Yu Zhao, Yongzhan Nie, Jing Wu
      Cellular Oncology.2023; 46(1): 145.     CrossRef
    • Correlated downregulation of VDR and CYP3A4 in colorectal cancer
      Hossein Sadeghi, Veys Hashemnia, Ehsan Nazemalhosseini-Mojarad, Mohammad Reza Ghasemi, Reza Mirfakhraie
      Molecular Biology Reports.2023; 50(2): 1385.     CrossRef
    • Multi-omics insights into the interplay between gut microbiota and colorectal cancer in the “microworld” age
      An-Jun Wang, Dingka Song, Yue-Mei Hong, Ning-Ning Liu
      Molecular Omics.2023; 19(4): 283.     CrossRef
    • Development of a Novel DNA Aptamer Targeting Colorectal Cancer Cell‐Derived Small Extracellular Vesicles as a Potential Diagnostic and Therapeutic Agent
      Byung Seok Cha, Young Jun Jang, Eun Sung Lee, Do Yeon Kim, Ji Su Woo, Jinseo Son, Seokjoon Kim, Jiye Shin, Jinjoo Han, Seokhwan Kim, Ki Soo Park
      Advanced Healthcare Materials.2023;[Epub]     CrossRef
    • Interaction of lncRNAs with mTOR in colorectal cancer: a systematic review
      Marziyeh Sadat Moslehian, Roya Shabkhizan, Mohammad Reza Asadi, Ahad Bazmani, Mahdi Mahdipour, Sanya Haiaty, Reza Rahbarghazi, Ebrahim Sakhinia
      BMC Cancer.2023;[Epub]     CrossRef
    • Hypermethylated GRIA4, a potential biomarker for an early non-invasive detection of metastasis of clinically known colorectal cancer
      Eva Lukacova, Tatiana Burjanivova, Petar Podlesniy, Marian Grendar, Eva Turyova, Ivana Kasubova, Ludovit Laca, Peter Mikolajcik, Eva Kudelova, Andrea Vanochova, Juraj Miklusica, Sandra Mersakova, Zora Lasabova
      Frontiers in Oncology.2023;[Epub]     CrossRef
    • Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer
      Ke Xu, Ai-Ru Yu, Shen-Bin Pan, Jie He
      World Journal of Gastroenterology.2023; 29(36): 5240.     CrossRef
    • Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation
      Saedeh Khadempar, Marzieh Lotfi, Fatemeh Haghiralsadat, Massoud Saidijam, Nasrin Ghasemi, Saeid Afshar
      Computers in Biology and Medicine.2023; 166: 107518.     CrossRef
    • Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways
      Humzah Postwala, Yesha Shah, Priyajeet S. Parekh, Mehul R. Chorawala
      Medical Oncology.2023;[Epub]     CrossRef
    • Assessing the Correlation between Helicobacter Pylori Infection and Increased Incidence of Colorectal Cancer, Gastric Atrophy, and Intestinal Metaplasia
      Kubilay İŞSEVER, Ali MUHTAROĞLU, Furkan Ali UYGUR, Muhammet Burak KAMBUROGLU
      Medical Records.2023; 5(Supplement): 22.     CrossRef
    • Functional Proteomics Characterization of the Role of SPRYD7 in Colorectal Cancer Progression and Metastasis
      Ana Montero-Calle, Sofía Jiménez de Ocaña, Ruth Benavente-Naranjo, Raquel Rejas-González, Rubén A. Bartolomé, Javier Martínez-Useros, Rodrigo Sanz, Jana Dziaková, María Jesús Fernández-Aceñero, Marta Mendiola, José Ignacio Casal, Alberto Peláez-García, Ro
      Cells.2023; 12(21): 2548.     CrossRef
    • The platinum coordination complex inhibits cell invasion-migration and epithelial-to-mesenchymal transition by altering the TGF-β-SMAD pathway in colorectal cancer
      Maha-Hamadien Abdulla, Aminah Ahmad Alzailai, Mansoor-Ali Vaali-Mohammed, Rehan Ahmad, Sabiha Fatima, Ahmed Zubaidi, Thamer bin Traiki, Amer Mahmood, Reem Hamoud Alrashoudi, Zahid Khan
      Frontiers in Pharmacology.2023;[Epub]     CrossRef
    • Integrated bioinformatics approach to unwind key genes and pathways involved in colorectal cancer
      Syeda Anjum Mobeen, Pallavi Saxena, Arun Kumar Jain, Ravi Deval, Khateef Riazunnisa, Dibyabhaba Pradhan
      Journal of Cancer Research and Therapeutics.2023; 19(7): 1766.     CrossRef
    • cGAS–STING signaling pathway in gastrointestinal inflammatory disease and cancers
      Xinxin Ke, Tao Hu, Mizu Jiang
      The FASEB Journal.2022;[Epub]     CrossRef
    • Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1
      Erin L. Symonds, Susanne K. Pedersen, Bernita Yeo, Hiba Al Naji, Susan E. Byrne, Amitesh Roy, Graeme P. Young
      Molecular Oncology.2022; 16(10): 2031.     CrossRef
    • Krill oil supplementation reduces the growth of CT-26 orthotopic tumours in Balb/c mice
      Abilasha Gayani Jayathilake, Elif Kadife, Nyanbol Kuol, Rodney Brain Luwor, Kulmira Nurgali, Xiao Qun Su
      BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
    • Predicted miRNAs suppressed cell proliferation and migration via FAK/VASP axis; Systems biology approach
      Asghar Mohammadi, Ghasem Ghasempour, Abbas Sahebghadam Lotfi, Mohammad Najafi
      Informatics in Medicine Unlocked.2022; 29: 100890.     CrossRef
    • The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer
      Maryam Alizadeh-Sedigh, Habibollah Mahmoodzadeh, Mohammad Sadegh Fazeli, Mohammad Haddadi-Aghdam, Ladan Teimoori-Toolabi
      Molecular and Cellular Probes.2022; 63: 101807.     CrossRef
    • Epigenetics and its Therapeutic Potential in Colorectal Cancer
      Mahsa Akbari Oryani, Afsaneh Tavasoli, Mohammad Amin Ghalavand, Rahele Zokaei Ashtiani, Alisam Rezaee, Rasadokht Mahmoudi, Hossein Golvari, Soroor Owrangi, Mehdi Soleymani-Goloujeh
      Epigenomics.2022; 14(11): 683.     CrossRef
    • Role of gene regulation and inter species interaction as a key factor in gut microbiota adaptation
      Shuang Gao, Muhammad Imran Khan, Fadia Kalsoom, Zhen Liu, Yanxin Chen, Zhengli Chen
      Archives of Microbiology.2022;[Epub]     CrossRef
    • Identification of a Genomic Instability-Related Long Noncoding RNA Prognostic Model in Colorectal Cancer Based on Bioinformatic Analysis
      Yu Liang, Hong-Xu Sun, Bin Ma, Qing-Kai Meng, Luca Falzone
      Disease Markers.2022; 2022: 1.     CrossRef
    • Novel multiplex stool-based assay for the detection of early-stage colon cancer in a Chinese population
      Hui-Hong Jiang, Si-Wei Xing, Xuan Tang, Ying Chen, Kang Lin, Lu-Wei He, Mou-Bin Lin, Er-Jiang Tang
      World Journal of Gastroenterology.2022; 28(24): 2705.     CrossRef
    • Genetic and epigenetic dependencies in colorectal cancer development
      Sehej Parmar, Hariharan Easwaran
      Gastroenterology Report.2022;[Epub]     CrossRef
    • Fecal biomarkers: Non-invasive diagnosis of colorectal cancer
      Qian Ding, Xiangxu Kong, Weilong Zhong, Wentian Liu
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • Long-term prognosis of curative endoscopic submucosal dissection for early colorectal cancer according to submucosal invasion: a multicenter cohort study
      Jongbeom Shin, Eun Ran Kim, Hyun Joo Jang, Dong Hoon Baek, Dong-Hoon Yang, Bo-In Lee, Kwang Bum Cho, Jin Woong Cho, Sung-Ae Jung, Su Jin Hong, Bong Min Ko, Jung-Won Jeon, Weon Jin Ko, Sun Moon Kim, Young Dae Kim, Kim Chan Gyoo, Gwang Ho Baik, In Kyung Yoo
      BMC Gastroenterology.2022;[Epub]     CrossRef
    • Chemotherapy induces feedback up-regulation of CD44v6 in colorectal cancer initiating cells through β-catenin/MDR1 signaling to sustain chemoresistance
      Shibnath Ghatak, Vincent C. Hascall, Nikos Karamanos, Roger R. Markwald, Suniti Misra
      Frontiers in Oncology.2022;[Epub]     CrossRef
    • Role of CTLA4 immunohistochemistry in the diagnosis of colon cancers
      Vishnu Narayanan, V Pavithra, Divya Dhanapal, Sandhya Sundaram, C. D Narayanan
      Indian Journal of Pathology and Microbiology.2022; 65(4): 791.     CrossRef
    • The potential value of miRNA-223 as a diagnostic biomarker for Egyptian colorectal patients
      Noha G. Bader El Din, Sally Farouk, Lubna O. Abdel-Salam, Ahmed Khairy
      European Journal of Gastroenterology & Hepatology.2021; 33(1): 25.     CrossRef
    • Role of gut microbiota in epigenetic regulation of colorectal Cancer
      Yinghui Zhao, Chuanxin Wang, Ajay Goel
      Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2021; 1875(1): 188490.     CrossRef
    • SIRT4 is the molecular switch mediating cellular proliferation in colorectal cancer through GLS mediated activation of AKT/GSK3β/CyclinD1 pathway
      Ying Cui, Yibing Bai, Jiani Yang, Yuanfei Yao, Chunhui Zhang, Chao Liu, Jiaqi Shi, QingWei Li, Jingchun Zhang, Xiaolin Lu, Yanqiao Zhang
      Carcinogenesis.2021; 42(3): 481.     CrossRef
    • Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center
      Călin Căinap, Ovidiu-Vasile Bochiş, Cătălin Vlad, Raluca Popita, Patriciu Achimaş-Cadariu, Andrei Havasi, Andreea Vidrean, Alexandra Dranca, Andra Piciu, Anne-Marie Constantin, Tiberiu Tat, Maniu Dana, Ovidiu Crişan, Cosmin Vasile Cioban, Ovidiu Bălăcescu
      Frontiers in Pharmacology.2021;[Epub]     CrossRef
    • A novel proteomics approach to epigenetic profiling of circulating nucleosomes
      Priscilla Van den Ackerveken, Alison Lobbens, Jean-Valery Turatsinze, Victor Solis-Mezarino, Moritz Völker-Albert, Axel Imhof, Marielle Herzog
      Scientific Reports.2021;[Epub]     CrossRef
    • Role of Stress-Survival Pathways and Transcriptomic Alterations in Progression of Colorectal Cancer: A Health Disparities Perspective
      Urbashi Basnet, Abhijeet R. Patil, Aditi Kulkarni, Sourav Roy
      International Journal of Environmental Research and Public Health.2021; 18(11): 5525.     CrossRef
    • Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
      Giulia Rizzo, Andrea Bertotti, Simonetta Maria Leto, Stefania Vetrano
      Journal of Experimental & Clinical Cancer Research.2021;[Epub]     CrossRef
    • Exosomes miR-22-3p Derived from Mesenchymal Stem Cells Suppress Colorectal Cancer Cell Proliferation and Invasion by Regulating RAP2B and PI3K/AKT Pathway
      Yan Wang, Changkun Lin, Alamgeer Yuchi
      Journal of Oncology.2021; 2021: 1.     CrossRef
    • Prognostic Score Model Based on Ten Differentially Methylated Genes for Predicting Clinical Outcomes in Patients with Adenocarcinoma of the Colon
      Gongping Sun, He Duan, Yuanhao Xing, Dewei Zhang
      Cancer Management and Research.2021; Volume 13: 5113.     CrossRef
    • Oral Delivery of Nucleic Acids with Passive and Active Targeting to the Intestinal Tissue Using Polymer-Based Nanocarriers
      Sagun Poudel, Prabhat R. Napit, Karen P. Briski, George Mattheolabakis
      Pharmaceutics.2021; 13(7): 1075.     CrossRef
    • Promising Epigenetic Biomarkers for the Early Detection of Colorectal Cancer: A Systematic Review
      Sorina Andreea Anghel, Corina-Bianca Ioniță-Mîndrican, Ioana Luca, Anca Lucia Pop
      Cancers.2021; 13(19): 4965.     CrossRef
    • Survival effect of probiotics in a rat model of colorectal cancer treated with capecitabine
      Graciela Gigola, Pedro Carriere, María Belén Novoa Díaz, Gabriela Perdigon, Ariel Osvaldo Zwenger, Claudia Gentili
      World Journal of Gastrointestinal Oncology.2021; 13(10): 1518.     CrossRef
    • Reviewing cancer’s biology: an eclectic approach
      Ibrahim Diori Karidio, Senay Hamarat Sanlier
      Journal of the Egyptian National Cancer Institute.2021;[Epub]     CrossRef
    • Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
      Hidayati Husainy Hasbullah, Marahaini Musa
      International Journal of Molecular Sciences.2021; 22(21): 11941.     CrossRef
    • Colon Cancer-Related Genes Identification and Function Study Based on Single-Cell Multi-Omics Integration
      Xuepu Sun, Yu Guo, Yu Zhang, Peng Zhao, Zhaoqing Wang, Zheng Wei, Haiquan Qiao
      Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
    • Epistatic effect of TLR3 and cGAS‐STING‐IKKε‐TBK1‐IFN signaling variants on colorectal cancer risk
      Calogerina Catalano, Miguel Inacio da Silva Filho, Christoph Frank, Shun Lu, Katerina Jiraskova, Veronika Vymetalkova, Miroslav Levy, Vaclav Liska, Ondrej Vycital, Alessio Naccarati, Ludmila Vodickova, Kari Hemminki, Pavel Vodicka, Alexander N. R. Weber,
      Cancer Medicine.2020; 9(4): 1473.     CrossRef
    • Proteomic investigations into resistance in colorectal cancer
      David I. Cantor, Harish R. Cheruku, Jack Westacott, Joo-Shik Shin, Abidali Mohamedali, Seong Boem Ahn
      Expert Review of Proteomics.2020; 17(1): 49.     CrossRef
    • Potential Use of Biotherapeutic Bacteria to Target Colorectal Cancer-Associated Taxa
      Garreth W. Lawrence, Máire Begley, Paul D. Cotter, Caitriona M. Guinane
      International Journal of Molecular Sciences.2020; 21(3): 924.     CrossRef
    • Clinical outcomes of submucosal colorectal cancer diagnosed after endoscopic resection: a focus on the need for surgery
      Yun Sik Choi, Wan Soo Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
      Intestinal Research.2020; 18(1): 96.     CrossRef
    • Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway
      Mingxing Ma, Xiaonan Wang, Ning Liu, Fengping Shan, Yong Feng
      International Immunopharmacology.2020; 83: 106388.     CrossRef
    • Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
      Christine Koulis, Raymond Yap, Rebekah Engel, Thierry Jardé, Simon Wilkins, Gemma Solon, Jeremy D. Shapiro, Helen Abud, Paul McMurrick
      Cancers.2020; 12(4): 812.     CrossRef
    • Novel biomarkers for the diagnosis and prognosis of colorectal cancer
      Hyung-Hoon Oh, Young-Eun Joo
      Intestinal Research.2020; 18(2): 168.     CrossRef
    • A novel epigenetic signature to predict recurrence-free survival in patients with colon cancer
      Qi-xin Dai, Yong-hui Liao, Xiao-hong Deng, Xiu-lin Xiao, Long Zhang, Lin Zhou
      Clinica Chimica Acta.2020; 508: 54.     CrossRef
    • Strategies to Increase the Participation Rate of Colorectal Cancer Screening
      Yoon Suk Jung
      Gut and Liver.2020; 14(3): 277.     CrossRef
    • Epigenetic Therapies in the Precision Medicine Era
      Michel Lopes Leite, Kamila Botelho Sampaio de Oliveira, Victor Albuquerque Cunha, Simoni Campos Dias, Nicolau Brito da Cunha, Fabricio F. Costa
      Advanced Therapeutics.2020;[Epub]     CrossRef
    • mTOR Signaling Combined with Cancer Stem Cell Markers as a Survival Predictor in Stage II Colorectal Cancer
      Ji Young Chang, Jae Hyun Kim, Joyeon Kang, Yehyun Park, Soo Jung Park, Jae Hee Cheon, Won Ho Kim, Hoguen Kim, Jae Jun Park, Tae Il Kim
      Yonsei Medical Journal.2020; 61(7): 572.     CrossRef
    • Survival Benefit of Palliative Primary Tumor Resection Based on Tumor Location in Patients with Metastatic Colorectal Cancer: A Single-center Retrospective Study
      Jae Hyun Kim, Sol Jin, Min Ji Jeon, Hyun Yeb Jung, Sanghwan Byun, Kyoungwon Jung, Sung Eun Kim, Won Moon, Moo In Park, Seun Ja Park
      The Korean Journal of Gastroenterology.2020; 76(1): 17.     CrossRef
    • USP18 directly regulates Snail1 protein through ubiquitination pathway in colorectal cancer
      Fakun Huang, Chengying Zheng, Longkai Huang, Changqing Lin, Jiaxing Wang
      Cancer Cell International.2020;[Epub]     CrossRef
    • RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer
      Huaiming Wang, Rongkang Huang, Wentai Guo, Xiusen Qin, Zifeng Yang, Zixu Yuan, Yingqi Wei, Chunlin Mo, Zhantao Zeng, Jian Luo, Jian Cai, Hui Wang
      Clinical Science.2020; 134(14): 1973.     CrossRef
    • P2X7R promotes angiogenesis and tumour‐associated macrophage recruitment by regulating the NF‐κB signalling pathway in colorectal cancer cells
      Chunhui Yang, Shuang Shi, Ying Su, Jing‐Shan Tong, Liangjun Li
      Journal of Cellular and Molecular Medicine.2020; 24(18): 10830.     CrossRef
    • Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review
      Janhavi R. Raut, Zhong Guan, Petra Schrotz-King, Hermann Brenner
      Clinical Epigenetics.2020;[Epub]     CrossRef

    • Integrative Analysis of the IQ Motif-Containing GTPase-Activating Protein Family Indicates That the IQGAP3-PIK3C2B Axis Promotes Invasion in Colon Cancer


      Zhuo Liu, Xiao Li, Jie Ma, Dechuan Li, Haixing Ju, Yong Liu, Yinbo Chen, Xujun He, Yuping Zhu
      OncoTargets and Therapy.2020; Volume 13: 8299.     CrossRef
    • Long Non-coding RNA LINC00115 Contributes to the Progression of Colorectal Cancer by Targeting miR-489-3p via the PI3K/AKT/mTOR Pathway
      Weiyu Feng, Baodong Li, Jinbang Wang, Huiliang Zhang, Yonggang Liu, Dongli Xu, Ke Cheng, Jing Zhuang
      Frontiers in Genetics.2020;[Epub]     CrossRef
    • Analysis of microRNA-34a expression profile and rs2666433 variant in colorectal cancer: a pilot study
      Manal S. Fawzy, Afaf T. Ibrahiem, Baraah T. Abu AlSel, Saleh A. Alghamdi, Eman A. Toraih
      Scientific Reports.2020;[Epub]     CrossRef
    • Drug Response Associated With and Prognostic lncRNAs Mediated by DNA Methylation and Transcription Factors in Colon Cancer
      Jiayu Zhang, Zhen Shen, Zheyu Song, Jian Luan, Yezhou Li, Tiancheng Zhao
      Frontiers in Genetics.2020;[Epub]     CrossRef

    • The SP1-Induced Long Noncoding RNA, LINC00339, Promotes Tumorigenesis in Colorectal Cancer via the miR-378a-3p/MED19 Axis


      Hua Ye, Wende Li, Kefeng Wu, Yi Liu, Yingnian Lv, Yuzhen Zhu, Hui Luo, Liao Cui
      OncoTargets and Therapy.2020; Volume 13: 11711.     CrossRef
    • Outcomes of stent insertion and mortality in obstructive stage IV colorectal cancer patients through 10 year duration
      Yong Eun Park, Yehyun Park, Soo Jung Park, Jae Hee Cheon, Won Ho Kim, Tae Il Kim
      Surgical Endoscopy.2019; 33(4): 1225.     CrossRef
    • AU-rich element-binding proteins in colorectal cancer
      Noémie Legrand, Dan A Dixon, Cyril Sobolewski
      World Journal of Gastrointestinal Oncology.2019; 11(2): 71.     CrossRef
    • Association between polymorphism in the promoter region of lncRNA GAS5 and the risk of colorectal cancer
      Yajie Wang, Shenshen Wu, Xi Yang, Xiaobo Li, Rui Chen
      Bioscience Reports.2019;[Epub]     CrossRef
    • Exosomes, metastases, and the miracle of cancer stem cell markers
      Zhe Wang, Margot Zöller
      Cancer and Metastasis Reviews.2019; 38(1-2): 259.     CrossRef
    • Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer
      Srinivas Patnaik, Anupriya
      Frontiers in Pharmacology.2019;[Epub]     CrossRef
    • Neurexophilin and PC‐esterase domain family member 4 (NXPE4) and prostate androgen‐regulated mucin‐like protein 1 (PARM1) as prognostic biomarkers for colorectal cancer
      Ya‐Rui Liu, Yang Hu, Ying Zeng, Zhi‐Xing Li, Hai‐Bo Zhang, Jun‐Li Deng, Guo Wang
      Journal of Cellular Biochemistry.2019; 120(10): 18041.     CrossRef
    • Identification of differentially expressed genes regulated by methylation in colon cancer based on bioinformatics analysis
      Yu Liang, Cheng Zhang, Dong-Qiu Dai
      World Journal of Gastroenterology.2019; 25(26): 3392.     CrossRef
    • Early-onset Colorectal Cancer
      Mo Ah Jeong, Hyoun Woo Kang
      The Korean Journal of Gastroenterology.2019; 74(1): 4.     CrossRef
    • Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
      Prashanth Rawla, Adam Barsouk, Andreas V. Hadjinicolaou, Alexander Barsouk
      Medical Sciences.2019; 7(8): 83.     CrossRef
    • The Expression Profile and Prognostic Significance of Metallothionein Genes in Colorectal Cancer
      Kuo-Chen Hung, Tsui-Chin Huang, Chia-Hsiung Cheng, Ya-Wen Cheng, Ding-Yen Lin, Jhen-Jia Fan, Kuen-Haur Lee
      International Journal of Molecular Sciences.2019; 20(16): 3849.     CrossRef
    • The Intricate Interplay between Epigenetic Events, Alternative Splicing and Noncoding RNA Deregulation in Colorectal Cancer
      Raheleh Amirkhah, Hojjat Naderi-Meshkin, Jaynish Shah, Philip Dunne, Ulf Schmitz
      Cells.2019; 8(8): 929.     CrossRef
    • TRPM7 deficiency suppresses cell proliferation, migration, and invasion in human colorectal cancer via regulation of epithelial-mesenchymal transition
      Fei Su, Bo-Fang Wang, Tao Zhang, Xiao-Ming Hou, Mao-Hui Feng
      Cancer Biomarkers.2019; 26(4): 451.     CrossRef
    • Assessment of Immuno-Histochemical Expression of MBD1 in Colorectal Adenocarcinoma and Its Correlations with Prognostic Factors
      Sholeh Ghaedamini, Mehdi Nikbakht, Mitra Soleimani
      Middle East Journal of Digestive Diseases.2019; 12(1): 39.     CrossRef
    • Promising Antineoplastic Actions of Melatonin
      Gaia Favero, Enrico Moretti, Francesca Bonomini, Russel J. Reiter, Luigi Fabrizio Rodella, Rita Rezzani
      Frontiers in Pharmacology.2018;[Epub]     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Genetic and epigenetic alterations of colorectal cancer
      Intest Res. 2018;16(3):327-337.   Published online July 27, 2018
      DOI: https://doi.org/10.5217/ir.2018.16.3.327
      Close
    • XML DownloadXML Download
    Related articles
    Genetic and epigenetic alterations of colorectal cancer
    Genetic and epigenetic alterations of colorectal cancer

    CRC Molecular Subtype Classification by Jass46

    Group 1Group 2Group 3Group 4Group 5
    Molecular features
     MSI statusMSI-HMSS, MSI-LMSS, MSI-LMainly MSSMSI-H
     CIMPHighHighLowNegativeNegative
     CINStableStableUnstableUnstableStable
     KRAS mutation+
     BRAF mutation++-
    Clinical features
     LocationRt>LtRt>LtLt>RtLt>RtRt>Lt
     SexF>MF>MM>FM>FM>F
     PrecursorSerrated polypSerrated polypSerrated polyp/adenomaAdenomaAdenoma

    CRC, colorectal cancer; MSI, microsatellite instability; MSI-H, MSI-high; MSS, microsatellite stable; MSI-L, MSI-low; CIMP, CpG island methylator phenotype; CIN, chromosomal instability; Rt, right; Lt, left; F, female; M, male.

    CRC Molecular Subtype Classification by TCGA (TCGA classification)10

    Hypermutated tumorNon-hypermutated tumor
    Frequent mutation>12 mutations per 106 bases (median number of total mutations, 728)<8.24 mutations per 106 bases (median number of total mutations, 58)
    Proportion of all CRCs1684
    Tumor siteColon and rectumCommon in right-side colon
    MSI statusStableHigh
    CIMP statusLowHigh
    APC gene mutation5181
    TP53 gene mutation2060
    Frequent affected genes (mutation frequency)ACVR2A (63), TGFBR2 (51), BRAF (46), MSH3 (40), and MSH6 (40)KRAS (43), PIK3CA (18), FBXW7 (11), SMAD4 (10), TCF7L2 (9), NRAS (9), FAM123B (7), CTNNB1 (β-catenin) (5), ACVR1B (4), SOX9 (4)
    SCNAs-Frequent
    WNT signaling activation9792
    TGF-β signaling inactivation8727
    PI3K signaling activation5350
    RTK/RAS signaling activation8059
    p53 signaling inactivation4764

    Values are presented as percentage.

    CRC, colorectal cancer; TCGA, The Cancer Genome Atlas; MSI, microsatellite instability; CIMP, CpG island methylator phenotype; SCNA, somatic copy number alteration; TGF, transforming growth factor; PI3K, phosphoinositide-3 kinase; RTK, receptor tyrosine kinase.

    CRC Molecular Subtype Classification by Linking Gene Expression Profiles with Corresponding Clinical Response to Cetuximab50

    SubtypesStem-likeaInflammatorybTransient-amplifyingcGoblet-likedEnterocytee
    Cetuximab resistantCetuximab sensitive
    Signature genesSFRP2, +ZEB1RARRES3CFTR, FLNACFTR, (FLNA)MUC2, TFF3MUC2, (TFF3)
    Biomarkers for qRT-PCRSFRP2+RARRES3+CFTR+, FLNA+CFTR+, FLNA−MUC2+, TFF3+MUC2+, TFF3−
    Biomarkers for IHCZEB1+-CFTRCFTRMUC2+, TFF3+MUC2+, TFF3−
    Correlated crypt locationBaseNSEitherEitherTopTop
    Disease-free survivalPoorIntermediatePoorGoodGoodIntermediate
    Adjuvant treatmentChemotherapy (FORFIRI)Chemotherapy (FORFIRI)Watchful surveillanceWatchful surveillanceWatchful surveillanceChemotherapy (FORFIRI)
    Metastatic treatmentChemotherapy (FORFIRI)Other therapyc-MET inhibitorCetuximabChemotherapy (FORFIRI) or other therapyOther therapy

    aHigh expression of WNT signaling targets plus stem cell, myoepithelial, and mesenchymal genes with low expression of differentiation markers.

    bComparatively high expression of chemokines and interferon-related genes.

    cHeterogeneous collection of samples with variable expression of stem cell and WNT-target genes.

    dHigh mRNA expression of goblet-specific MUC2 and TFF3.

    eHigh expression of enterocyte-specific genes.

    CRC, colorectal cancer; qRT-PCR, real-time quantitative RT-PCR; IHC, immunohistochemistry.

    CRC Molecular Subtype Classification by Gene Expression Profiling (CMS Classification)54

    CMS1 (MSI-immune)CMS2 (canonical)CMS3 (metabolic)CMS4 (mesenchymal)
    % of all CRCsa14371323
    Mutation profileBRAF, TGFBR2APC, TP53, CINKRAS, APC-
    SCNALowHighIntermediateHigh
    MSI statusMSI-highMSS/MSI-lowMSS/MSI-lowMSS/MSI-low
    CIMPHigh/lowNegativeLowNegative
    Pathway analysisJAK/STAT and caspases pathwayWNT and MYC activation; cell cycle pathwayMetabolic dysregulation; epithelial signatureTGF-β activation; stromal infiltration, EMT activation, matrix remodeling; angiodysplasia
    MicroRNA-High expression of the miR-17-92 clusterLow expression of let-7 miR familyLow expression of miR-200 family
    Clinical and pathological variables
     Clinical characteristicsFemale, old-onset---
     SiteRight colonLeft colon and rectumLeft, right colon, and rectumLeft colon and rectum
     Stage---Advanced stage (III and IV)
     Histologic gradeHigher histologic grade---
     PrognosisWorse survival after relapseSuperior survival after relapse-Worse relapse-free and overall survival

    aMixed type (15%).

    CRC, colorectal cancer; CMS, consensus molecular subtype; CIN, chromosomal instability; SCNA, somatic copy number alteration; MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype; JAK, Janus kinase; STAT, signal transducers and activators of transcription; TGF, transforming growth factor; EMT, epithelial-mesenchymal transition.

    CRC Molecular Subtype Classification by MSI, CIMP, and Mutations in BRAF and KRAS57

    Type 1Type 2Type 3Type 4Type 5
    % of CRCs7426477
    MSIMSI-highMSS/MSI-lowMSS/MSI-lowMSS/MSI-lowMSS/MSI-low
    CIMPPositivePositiveNegativeNegativeNegative
    BRAFMutationMutationWild-typeWild-typeWild-type
    KRASWild-typeWild-typeMutationWild-typeWild-type
    CRC specific 5-yr survival (%)89.549.272.482.593.1
    Clinical characteristicsOldest-onset, femaleOld-onset, female-MaleYoungest-onset, CRC family history
    SiteProximal colonProximal colon-Distal colon and rectumProximal colon
    Proposed molecular pathwayMSI
    BRAF mutation
    CIMP-positive    		BRAF mutation
    CIMP-positive    		KRAS mutationCanonical pathway with APC mutationMSI

    CRC, colorectal cancer; MSI, microsatellite instability; CIMP, CpG island methylator phenotype; MSS, microsatellite stable.
    Table 1 CRC Molecular Subtype Classification by Jass46

    CRC, colorectal cancer; MSI, microsatellite instability; MSI-H, MSI-high; MSS, microsatellite stable; MSI-L, MSI-low; CIMP, CpG island methylator phenotype; CIN, chromosomal instability; Rt, right; Lt, left; F, female; M, male.

    Table 2 CRC Molecular Subtype Classification by TCGA (TCGA classification)10

    Values are presented as percentage.

    CRC, colorectal cancer; TCGA, The Cancer Genome Atlas; MSI, microsatellite instability; CIMP, CpG island methylator phenotype; SCNA, somatic copy number alteration; TGF, transforming growth factor; PI3K, phosphoinositide-3 kinase; RTK, receptor tyrosine kinase.

    Table 3 CRC Molecular Subtype Classification by Linking Gene Expression Profiles with Corresponding Clinical Response to Cetuximab50

    aHigh expression of WNT signaling targets plus stem cell, myoepithelial, and mesenchymal genes with low expression of differentiation markers.

    bComparatively high expression of chemokines and interferon-related genes.

    cHeterogeneous collection of samples with variable expression of stem cell and WNT-target genes.

    dHigh mRNA expression of goblet-specific MUC2 and TFF3.

    eHigh expression of enterocyte-specific genes.

    CRC, colorectal cancer; qRT-PCR, real-time quantitative RT-PCR; IHC, immunohistochemistry.

    Table 4 CRC Molecular Subtype Classification by Gene Expression Profiling (CMS Classification)54

    aMixed type (15%).

    CRC, colorectal cancer; CMS, consensus molecular subtype; CIN, chromosomal instability; SCNA, somatic copy number alteration; MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype; JAK, Janus kinase; STAT, signal transducers and activators of transcription; TGF, transforming growth factor; EMT, epithelial-mesenchymal transition.

    Table 5 CRC Molecular Subtype Classification by MSI, CIMP, and Mutations in BRAF and KRAS57

    CRC, colorectal cancer; MSI, microsatellite instability; CIMP, CpG island methylator phenotype; MSS, microsatellite stable.

    Table 1

    Table 2

    Table 3

    Table 4

    Table 5

    Intest Res : Intestinal Research
    © Korean Association for the Study of Intestinal Diseases.
    Close layer
    TOP